Regeneron Pharmaceuticals, Inc.

Kelly Frye

Daniel B Dix

Eric Steven Furfine

Kenneth S Graham

Susan Kautz

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

VEGF antagonist formulations suitable for intravitreal administration

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Citrate buffered VEGF antagonist formulations

Formulations of VEG antagonist fusion proteins and method of manufacturing them

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.

Method of manufacturing VEGF antagonist fusion proteins

VEGF specific fusion protein antagonist formulations

Stable VEGF antagonist formulations

Stable liquid formulations of dimer VEGF antagonists

VEGF antagonist formulations for intravitreal administration

Growing community of inventors

Mendham, NJ, United States of America

Kelly Frye